Novo Nordisk was the first to invest in the GLP-1R/amylin long-acting combination formulation, CagriSema (semaglutide 2.4mg + cagrilintide 2.4mg), aiming to develop a next-generation weight loss drug that surpasses semaglutide in efficacy, countering the challenges posed by zepbond and other potential competitors
Although subcutaneous semaglutide is already approved by the FDA for cardiovascular risk reduction in adults with type 2 diabetes and established atherosclerotic cardiovascular disease, oral semaglutide is currently approved only for glycaemic control
Considerations and Precautions Before considering semaglutide as a weight loss treatment, it is crucial to understand and address certain considerations and precautions
The through-line here: matching a medication to a person is genuinely complex, and it is the kind of thing a prescriber does with your full chart in front of them
Bariatric Surgery: For people with severe obesity, bariatric surgery may be considered when lifestyle changes and medication have not achieved sufficient weight loss